Amgen
Amgen Inc. (Nasdaq: AMGN) discovers, develops, manufactures and delivers human therapeutics, including biologic and small-molecule medicines for diseases such as cancer, cardiovascular and bone disorders, inflammatory conditions and rare diseases. Its customers include healthcare providers, hospitals, dialysis centers… From the company’s description.
In fiscal 2025, Amgen reported revenue of $36.75B, up 10.0% from fiscal 2024, and net income of $7.71B. Its operating margin was 24.7%, and operations generated $9.96B in cash. Over the twelve months to Jun 30, 2026, revenue was $38.09B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Amgen does
In the company’s own words
Amgen Inc. (Nasdaq: AMGN) discovers, develops, manufactures and delivers human therapeutics, including biologic and small-molecule medicines for diseases such as cancer, cardiovascular and bone disorders, inflammatory conditions and rare diseases. Its customers include healthcare providers, hospitals, dialysis centers and pharmacies; in the United States, pharmaceutical wholesalers are its principal distribution channel. Amgen operates as one reportable segment, human therapeutics, and sells medicines through its own affiliates and in collaboration with other companies in approximately 100 countries. Major products include Prolia, Repatha, Otezla, Enbrel, Evenity, Xgeva, Tepezza, Blincyto and Tezspire. The company also develops and markets biosimilars, including WEZLANA and BKEMV. Product sales totaled $35.1 billion in fiscal 2025, with 73% in the United States and 27% in other regions. Amgen acquired Horizon Therapeutics in 2023, adding products including Tepezza and Krystexxa, and acquired ChemoCentryx in 2022, which developed TAVNEOS.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- THOUSAND OAKS, CA
- Fiscal year end
- December
- CIK
- 318154
- SIC
- 2836
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Amgen — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Amgen · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Amgen’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Amgen’s bonds, as funds hold them
Funds report holding 41 issues of Amgen’s debt, $8.56B at market value — what funds hold, not the company’s total debt. Weighted-average coupon 4.63%, maturing 2026 to 2063.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Amgen and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Amgen's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Amgen's last four quarterly filings that the numbers alone won't show?”